LumiSTAR develops various platforms by exploiting or packaging bioimaging and iPSC technologies together to make cellular response visualizable in real time, using our designed protein-based indicators with different dynamic ranges for long-term observation and measurements, as they are non-toxic to the cells. Thus, drug efficacy and toxicity can be studied at early stage to shorten the process of product development.
1. iPSC High Content/Throughput Screening Platform:
* For Drug Development:
- Models for cardiac and neurodegenerative diseases are available.
- Drug efficacy study
- Toxicity can be evaluated at early stage.
- Support phenotypic screening
* For Cell Therapy:
- iPSC cell reprogramming and differentiation development
- Functional testing platform for iPSC derived cells
2. Pseudovirus High Throughput Imaging Screening Platform
- Pseudovirus construction for various strains
- Neutralizing antibody screening, vaccine validation and drug Screening
- Customized service is available
3. Personalized/Precision Medicine
LumiSTAR’s platform has helped our client successfully license out their drug pipeline.